Sign In
Buy CRIS
$0.500
-0.0025 (-0.498%)
At Close: Jun 03, 2026
Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023
06:25pm, Thursday, 27'th Jul 2023
LEXINGTON, Mass. , July 27, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for
Curis (CRIS) Reports Q1 Loss, Misses Revenue Estimates
07:01pm, Thursday, 04'th May 2023
Curis (CRIS) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.18 per share a year ago.
Curis to Present at Upcoming Healthcare Conferences in April
08:00am, Monday, 03'rd Apr 2023
LEXINGTON, Mass. , April 3, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced
Curis, Inc. (CRIS) Q4 2022 Earnings Call Transcript
12:22pm, Monday, 13'th Mar 2023
Curis, Inc. (NASDAQ:CRIS ) Q4 2022 Earnings Conference Call March 13, 2023 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer James Dentzer - President and Chief Executive Office
Curis (CRIS) Reports Q4 Loss, Misses Revenue Estimates
10:44am, Monday, 13'th Mar 2023
Curis (CRIS) delivered earnings and revenue surprises of 14.29% and 4.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Curis Reschedules Fourth Quarter 2022 Business Update and Conference Call
07:09pm, Wednesday, 08'th Mar 2023
LEXINGTON, Mass. , March 8, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced today
Curis to Release Fourth Quarter 2022 Financial Results and Hold Conference Call on March 9, 2023
04:01pm, Thursday, 02'nd Mar 2023
LEXINGTON, Mass. , March 2, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
05:14pm, Tuesday, 13'th Dec 2022 Benzinga
Gainers
OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.
Netcapital Inc. (NASDAQ: NCPL
Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
06:05pm, Monday, 12'th Dec 2022 Benzinga
Gainers
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG Molecular Diagnostics, last month, posted a Q3 loss of $0.41 per share
Curis to Host Webcast to Discuss Updated Emavusertib Clinical Data in Leukemia
11:08pm, Monday, 05'th Dec 2022
Curis to review results during conference call, featuring commentary by Dr. Eric Winer, M.D., Dana-Farber Cancer Institute, on Monday, December 12 at 10:00 a.m.
Curis (CRIS) Reports Q3 Loss, Misses Revenue Estimates
10:45pm, Wednesday, 09'th Nov 2022 Zacks Investment Research
Curis (CRIS) delivered earnings and revenue surprises of 17.65% and 6.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Curis, Inc. (CRIS) Q3 2022 Earnings Call Transcript
07:36pm, Wednesday, 09'th Nov 2022
Curis, Inc. (NASDAQ:CRIS ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Craig West – Vice President-Investor Relations and Corporate Communications Jim Dentzer �
Curis (CRIS) Reports Q3 Loss, Misses Revenue Estimates
06:48pm, Wednesday, 09'th Nov 2022
Curis (CRIS) delivered earnings and revenue surprises of 17.65% and 6.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Agenus (AGEN) Reports Q3 Loss, Tops Revenue Estimates
02:25pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
Agenus (AGEN) delivered earnings and revenue surprises of -5.56% and 14.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Curis Is A Speculative Play That Could Produce Solid Returns
10:18am, Friday, 21'st Oct 2022
A look at a couple of drugs in Curis pipeline that could generate some big returns if they are able to gain approval from the FDA. The company should have enough capital to fund operations through 202
